Apolipoprotein AIV: a potent endogenous inhibitor of lipid oxidation

1998 ◽  
Vol 274 (5) ◽  
pp. H1836-H1840 ◽  
Author(s):  
Xiaofa Qin ◽  
Debi K. Swertfeger ◽  
Shuqin Zheng ◽  
David Y. Hui ◽  
Patrick Tso

Overexpression of apolipoprotein (apo) AIV in transgenic mice confers significant protection against atherosclerosis in apoE knockout animals even in the presence of a more severe atherogenic lipid profile. Because lipoprotein oxidation has been recognized to be pivotal in development of atherosclerosis, the antioxidative activity of apoAIV was investigated. Fasting intestinal lymph was used to mimic conditions in the interstitial fluid, the potential site for lipoprotein oxidation in vivo. ApoAIV (10 μg/ml) significantly inhibited copper-mediated oxidation of lymph. This inhibitory effect was further evaluated using purified low-density lipoprotein. Addition of apoAIV (2.5 μg/ml) increased the time of 50% conjugated diene formation by 2.4-fold, whereas apoE or BSA did not show such a protection even at 20 μg/ml. Addition of apoAIV during the propagation phase also resulted in a dose-dependent inhibition. ApoAIV also protected macrophage-induced oxidation of fasting lymph. These results provide the first evidence that apoAIV is a potent endogenous antioxidant.

1993 ◽  
Vol 75 (1) ◽  
pp. 167-172 ◽  
Author(s):  
D. C. Crossman ◽  
M. R. Dashwood ◽  
G. W. Taylor ◽  
R. Wellings ◽  
R. W. Fuller

The mechanism of action of the antiasthmatic drug sodium cromoglycate (SCG) is unclear. One possibility is that SCG antagonizes the effects of the tachykinin substance P (SP), an agent known to cause airway edema. However, when SP is inhaled by humans, it has no demonstrable effect on airway function; therefore, the possibility that SCG prevents SP-induced changes in microvascular permeability was examined in human skin in vivo where potent edema-producing effects are seen. SCG (5–500 nmol) caused significant (P < 0.05) dose-dependent inhibition of SP-induced edema (wheal) formation when coadministered by intradermal injection. There was no effect on the nonreceptor-mediated flare response. SCG also significantly (P < 0.05) inhibited the wheal response to the related tachykinin neurokinin B but had no inhibitory effect on the cutaneous responses to histamine and prostaglandin E2. In addition, SCG (0.1–10 mM) caused dose-dependent inhibition of binding of SP labeled with 125I-labeled Bolton-Hunter to a number of tissues known to contain SP binding sites, as assessed by autoradiography. These concentrations were equivalent to the final concentrations of SCG found to inhibit the wheal response in the skin. The possibility that SCG interacted with SP was investigated both by gel filtration and high-performance liquid chromatography. No strong interaction was demonstrated with an 8,000 M excess of SCG under both hydrophobic and hydrophilic conditions. These results raise the possibility that SCG may have tachykinin antagonist properties.


2008 ◽  
Vol 56 (10) ◽  
pp. 3609-3615 ◽  
Author(s):  
Wai Mun Loke ◽  
Julie M. Proudfoot ◽  
Allan J. Mckinley ◽  
Paul W. Needs ◽  
Paul A. Kroon ◽  
...  

RSC Advances ◽  
2015 ◽  
Vol 5 (104) ◽  
pp. 85806-85815 ◽  
Author(s):  
Ya-Ting Lee ◽  
You-Liang Hsieh ◽  
Yen-Hung Yeh ◽  
Chih-Yang Huang

15 phenolic amides (PAs) have been synthesized and examinedin vitrousing four tests: (1) prevention of Cu2+-induced human low-density lipoprotein oxidation, (2) scavenging of stable radicals, (3) anti-inflammatory activity, and (4) scavenging of superoxide radicals.


2005 ◽  
Vol 28 (6) ◽  
pp. 1095-1097 ◽  
Author(s):  
Phuong Thien Thuong ◽  
MinKyun Na ◽  
Nguyen Duy Su ◽  
Rack Seon Seong ◽  
Young Mi Lee ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document